Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension

Nicole B. Gabler, Benjamin French, Brian L. Strom, Ziyue Liu, Harold I. Palevsky, Darren B. Taichman, Steven M. Kawut, Scott D. Halpern

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background: Recently studied therapies for pulmonary arterial hypertension (PAH) have improved outcomes among populations of patients, but little is known about which patients are most likely to respond to specific treatments. Differences in endothelin-1 biology between sexes and between whites and blacks may lead to differences in patients' responses to treatment with endothelin receptor antagonists (ERAs). Methods: We conducted pooled analyses of deidentified, patient-level data from six randomized placebo-controlled trials of ERAs submitted to the US Food and Drug Administration to elucidate heterogeneity in treatment response. We estimated the interaction between treatment assignment (ERA vs placebo) and sex and between treatment and white or black race in terms of the change in 6-min walk distance from baseline to 12 weeks. Results: Trials included 1,130 participants with a mean age of 49 years; 21% were men, 74% were white, and 6% were black. The placebo-adjusted response to ERAs was 29.7 m (95% CI, 3.7-55.7 m) greater in women than in men(P =.03). The placebo-adjusted response was 42.2 m for whites and - 1.4 m for blacks, a difference of 43.6 m (95% CI,-3.5-90.7 m) (P =.07). Similar results were found in sensitivity analyses and in secondary analyses using the outcome of absolute distance walked. Conclusions: Women with PAH obtain greater responses to ERAs than do men, and whites may experience a greater treatment benefit than do blacks. This heterogeneity in treatment-response may reflect pathophysiologic differences between sexes and races or distinct disease phenotypes.

Original languageEnglish (US)
Pages (from-to)20-26
Number of pages7
JournalChest
Volume141
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Pulmonary Hypertension
Sex Characteristics
Placebos
Therapeutics
Endothelin Receptor Antagonists
Endothelin-1
United States Food and Drug Administration
Randomized Controlled Trials
Phenotype
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Gabler, N. B., French, B., Strom, B. L., Liu, Z., Palevsky, H. I., Taichman, D. B., ... Halpern, S. D. (2012). Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest, 141(1), 20-26. https://doi.org/10.1378/chest.11-0404

Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. / Gabler, Nicole B.; French, Benjamin; Strom, Brian L.; Liu, Ziyue; Palevsky, Harold I.; Taichman, Darren B.; Kawut, Steven M.; Halpern, Scott D.

In: Chest, Vol. 141, No. 1, 01.2012, p. 20-26.

Research output: Contribution to journalArticle

Gabler, NB, French, B, Strom, BL, Liu, Z, Palevsky, HI, Taichman, DB, Kawut, SM & Halpern, SD 2012, 'Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension', Chest, vol. 141, no. 1, pp. 20-26. https://doi.org/10.1378/chest.11-0404
Gabler, Nicole B. ; French, Benjamin ; Strom, Brian L. ; Liu, Ziyue ; Palevsky, Harold I. ; Taichman, Darren B. ; Kawut, Steven M. ; Halpern, Scott D. / Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. In: Chest. 2012 ; Vol. 141, No. 1. pp. 20-26.
@article{656e6d284e5c424ebc357d80482fe0f4,
title = "Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension",
abstract = "Background: Recently studied therapies for pulmonary arterial hypertension (PAH) have improved outcomes among populations of patients, but little is known about which patients are most likely to respond to specific treatments. Differences in endothelin-1 biology between sexes and between whites and blacks may lead to differences in patients' responses to treatment with endothelin receptor antagonists (ERAs). Methods: We conducted pooled analyses of deidentified, patient-level data from six randomized placebo-controlled trials of ERAs submitted to the US Food and Drug Administration to elucidate heterogeneity in treatment response. We estimated the interaction between treatment assignment (ERA vs placebo) and sex and between treatment and white or black race in terms of the change in 6-min walk distance from baseline to 12 weeks. Results: Trials included 1,130 participants with a mean age of 49 years; 21{\%} were men, 74{\%} were white, and 6{\%} were black. The placebo-adjusted response to ERAs was 29.7 m (95{\%} CI, 3.7-55.7 m) greater in women than in men(P =.03). The placebo-adjusted response was 42.2 m for whites and - 1.4 m for blacks, a difference of 43.6 m (95{\%} CI,-3.5-90.7 m) (P =.07). Similar results were found in sensitivity analyses and in secondary analyses using the outcome of absolute distance walked. Conclusions: Women with PAH obtain greater responses to ERAs than do men, and whites may experience a greater treatment benefit than do blacks. This heterogeneity in treatment-response may reflect pathophysiologic differences between sexes and races or distinct disease phenotypes.",
author = "Gabler, {Nicole B.} and Benjamin French and Strom, {Brian L.} and Ziyue Liu and Palevsky, {Harold I.} and Taichman, {Darren B.} and Kawut, {Steven M.} and Halpern, {Scott D.}",
year = "2012",
month = "1",
doi = "10.1378/chest.11-0404",
language = "English (US)",
volume = "141",
pages = "20--26",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension

AU - Gabler, Nicole B.

AU - French, Benjamin

AU - Strom, Brian L.

AU - Liu, Ziyue

AU - Palevsky, Harold I.

AU - Taichman, Darren B.

AU - Kawut, Steven M.

AU - Halpern, Scott D.

PY - 2012/1

Y1 - 2012/1

N2 - Background: Recently studied therapies for pulmonary arterial hypertension (PAH) have improved outcomes among populations of patients, but little is known about which patients are most likely to respond to specific treatments. Differences in endothelin-1 biology between sexes and between whites and blacks may lead to differences in patients' responses to treatment with endothelin receptor antagonists (ERAs). Methods: We conducted pooled analyses of deidentified, patient-level data from six randomized placebo-controlled trials of ERAs submitted to the US Food and Drug Administration to elucidate heterogeneity in treatment response. We estimated the interaction between treatment assignment (ERA vs placebo) and sex and between treatment and white or black race in terms of the change in 6-min walk distance from baseline to 12 weeks. Results: Trials included 1,130 participants with a mean age of 49 years; 21% were men, 74% were white, and 6% were black. The placebo-adjusted response to ERAs was 29.7 m (95% CI, 3.7-55.7 m) greater in women than in men(P =.03). The placebo-adjusted response was 42.2 m for whites and - 1.4 m for blacks, a difference of 43.6 m (95% CI,-3.5-90.7 m) (P =.07). Similar results were found in sensitivity analyses and in secondary analyses using the outcome of absolute distance walked. Conclusions: Women with PAH obtain greater responses to ERAs than do men, and whites may experience a greater treatment benefit than do blacks. This heterogeneity in treatment-response may reflect pathophysiologic differences between sexes and races or distinct disease phenotypes.

AB - Background: Recently studied therapies for pulmonary arterial hypertension (PAH) have improved outcomes among populations of patients, but little is known about which patients are most likely to respond to specific treatments. Differences in endothelin-1 biology between sexes and between whites and blacks may lead to differences in patients' responses to treatment with endothelin receptor antagonists (ERAs). Methods: We conducted pooled analyses of deidentified, patient-level data from six randomized placebo-controlled trials of ERAs submitted to the US Food and Drug Administration to elucidate heterogeneity in treatment response. We estimated the interaction between treatment assignment (ERA vs placebo) and sex and between treatment and white or black race in terms of the change in 6-min walk distance from baseline to 12 weeks. Results: Trials included 1,130 participants with a mean age of 49 years; 21% were men, 74% were white, and 6% were black. The placebo-adjusted response to ERAs was 29.7 m (95% CI, 3.7-55.7 m) greater in women than in men(P =.03). The placebo-adjusted response was 42.2 m for whites and - 1.4 m for blacks, a difference of 43.6 m (95% CI,-3.5-90.7 m) (P =.07). Similar results were found in sensitivity analyses and in secondary analyses using the outcome of absolute distance walked. Conclusions: Women with PAH obtain greater responses to ERAs than do men, and whites may experience a greater treatment benefit than do blacks. This heterogeneity in treatment-response may reflect pathophysiologic differences between sexes and races or distinct disease phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=84855440266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855440266&partnerID=8YFLogxK

U2 - 10.1378/chest.11-0404

DO - 10.1378/chest.11-0404

M3 - Article

C2 - 21940766

AN - SCOPUS:84855440266

VL - 141

SP - 20

EP - 26

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -